Microfluidic Organotypic Model for Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients (MOTEM)

I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Status: Unknown

Conditions: Osteoarthritis

Treatments: Other: use of patient-derived biological samples

Study type: Observational

Funder types: Other

Identifiers

NCT03347500

MOTEM

Details and patient eligibility

About

Osteoarthritis (OA) is the fastest growing cause of disability worldwide due to population ageing and increasing obesity incidence. Obese individuals have a higher risk of OA insurgence and severe progression due to several risk factors, including their systemic inflammation state and superior migratory ability of monocytes. In the present project we aim at the development of a novel 3D microfluidic organotypic model resembling the joint to investigate the migration ability of monocytes from obese and non-obese OA patients.

We hypothesize that monocytes from obese OA patients display superior migration ability and a specific pattern of chemokine surface receptors compared to monocytes from non-obese OA patients. We also hypothesize that these features lead to a superior infiltration of monocytes/macrophages to the synovial membrane in obese OA patients. Based on this, our main aim will be to highlight differences between Mo from obese and non-obese OA patients in terms of surface receptors and migration ability in a microfluidic organotypic model.

Enrollment: 88 estimated patients

Sex: All

Ages: 60 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Obese OA patients

• Subscription of informed consent
• BMI ≥ 30
• age between 60-80 years included
• Kelgrenn-Lawrence equal or superior to grade III
• presence of synovitis
• patients undergoing knee replacement
• suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice

Non-obese OA patients

• Subscription of informed consent
• BMI ≤ 28
• age between 60-80 years included
• Kelgrenn-Lawrence equal or superior to grade III
• presence of synovitis
• patients undergoing knee replacement
• suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice

Exclusion criteria

Obese OA patients - HCV, HIV, HBV, TPHA infection

Non-obese OA patients

• HCV, HIV, HBV, TPHA infection

Trial design

88 participants in 2 patient groups

obese OA patients

Description:

Use of patient-derived biological samples Inclusion Criteria: * Subscription of informed consent * BMI ≥ 30 * age between 60-80 years included * Kelgrenn-Lawrence equal or superior to grade III * presence of synovitis * patients undergoing knee replacement * suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice Exclusion criteria: - HCV, HIV, HBV, TPHA infection

Treatment:

Other: use of patient-derived biological samples

Non-obese OA patients

Description:

Use of patient-derived biological samples Inclusion criteria: * Subscription of informed consent * BMI ≤ 28 * age between 60-80 years included * Kelgrenn-Lawrence equal or superior to grade III * presence of synovitis * patients undergoing knee replacement * suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice Exclusion criteria: - HCV, HIV, HBV, TPHA infection

Treatment:

Other: use of patient-derived biological samples